Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Focal Segmental Glomerulosclerosis Market CAGR Outlook And Future Development
The focal segmental glomerulosclerosis market size has experienced significant growth in recent years. It is projected to expand from $1.57 billion in 2025 to $1.69 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.6%. This historical growth can be ascribed to factors such as the prevalence of proteinuria, the burden of chronic kidney disease, the utilization of corticosteroids, the expansion of nephrology clinics, and advancements in dialysis infrastructure.
The focal segmental glomerulosclerosis market is projected to experience robust expansion over the coming years, forecast to reach $2.24 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.2%. This anticipated growth during the forecast period is fueled by advancements such as precision nephrology, the identification of early disease biomarkers, progress in biologic drug development, the expansion of transplant programs, and increased funding for rare kidney diseases. Key trends anticipated for this period involve a heightened emphasis on targeted immunosuppressive therapy, the increasing use of combination drug regimens, broader early diagnostic screening initiatives, a growing reliance on renin-angiotensin system inhibitors, and improved kidney transplant preparedness.
Get A Free Sample Report With In-Depth Market Insights:
Focal Segmental Glomerulosclerosis Market Expansion Drivers: What’s Shaping Future Growth?
An increasing prevalence of kidney diseases is anticipated to fuel the growth of the focal segmental glomerulosclerosis market in the coming years. Kidney diseases are conditions that compromise the kidneys’ function and structure, thereby impacting their capacity to filter waste, maintain fluid balance, and regulate essential bodily functions. The growing incidence of kidney diseases is primarily linked to diabetes, as consistently high blood sugar levels over time damage the filtering units of the kidneys, leading to diabetic nephropathy. Focal segmental glomerulosclerosis itself represents the progressive scarring of kidney filters, serving as an important indicator and target for understanding, diagnosing, and managing chronic kidney diseases. For example, in August 2025, the American Kidney Fund, a U.S.-based nonprofit organization, reported that 35.5 million Americans are living with chronic kidney disease (CKD), approximately 815,000 Americans are experiencing kidney failure, and nearly 555,000 Americans are currently on dialysis. Thus, the escalating prevalence of kidney diseases is a significant driver for the focal segmental glomerulosclerosis market.
Focal Segmental Glomerulosclerosis Market Segment Landscape And Growth Outlook
The focal segmental glomerulosclerosis market covered in this report is segmented –
1) By Disease Type: Primary Focal Segmental Glomerulosclerosis, Secondary Focal Segmental Glomerulosclerosis
2) By Treatment: Drug Therapy, Dialysis, Kidney Transplant, Other Treatments
3) By Drug Class: Immunosuppressants, Angiotensin Inhibitors, Corticosteroids
4) By Route Of Administration: Oral, Parenteral
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Primary Focal Segmental Glomerulosclerosis: Idiopathic Focal Segmental Glomerulosclerosis, Genetic Or Familial Focal Segmental Glomerulosclerosis, Collapsing Variant, Tip Lesion Variant, Cellular Variant, Perihilar Variant
2) By Secondary Focal Segmental Glomerulosclerosis: Virus-Associated Focal Segmental Glomerulosclerosis, Drug-Induced Focal Segmental Glomerulosclerosis, Adaptive Or Compensatory Focal Segmental Glomerulosclerosis, Other Secondary Causes
Focal Segmental Glomerulosclerosis Market Strategic Trends: What Defines The Next Growth Phase?
Major companies in the focal segmental glomerulosclerosis market are concentrating on developing innovative therapies, such as non-immunosuppressive oral medication, to enhance patient outcomes and minimize treatment side effects. These oral drugs treat the disease without weakening the immune system, managing focal segmental glomerulosclerosis by directly targeting kidney damage and avoiding immune-related adverse effects. For example, in May 2025, Travere Therapeutics Inc., a US-based biopharmaceutical company, obtained traditional approval from the U.S. Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) for FILSPARI (sparsentan), specifically for the treatment of focal segmental glomerulosclerosis (FSGS). FILSPARI is a first-in-class therapy that operates by simultaneously blocking the endothelin type A receptor (ETAR) and the angiotensin II type 1 receptor (AT1R). This dual mechanism substantially reduces proteinuria in conditions like FSGS and IgA nephropathy. In comparison to existing treatments, FILSPARI delivers improved kidney protection while upholding a strong safety profile.
Focal Segmental Glomerulosclerosis Market Competitive Landscape: Who Leads The Industry?
Major companies operating in the focal segmental glomerulosclerosis market are Pfizer Inc., Merck And Co. Inc., Sanofi S.A., Eli Lilly and Company, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Mallinckrodt ARD LLC, Kyowa Kirin Co. Ltd., Aurinia Pharmaceuticals Inc., Travere Therapeutics Inc., Eledon Pharmaceuticals Inc., ZyVersa Therapeutics Inc., Complexa Inc., Certa Therapeutics, Delta 4 GmbH, Dimerix Limited, Goldfinch Bio Inc., Oraxion Therapeutics Inc., Variant Pharmaceuticals Inc.
View The Full Focal Segmental Glomerulosclerosis Market Report:
Focal Segmental Glomerulosclerosis Market Global Footprint: Which Region Leads The Market?
North America was the largest region in the focal segmental glomerulosclerosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the focal segmental glomerulosclerosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
